ERBB2 and cancer: Although we suggest that different epitope recognition impacts the anti-tumor response of CAR-T cells, we observed that IgG1 formats of both Ab8 and trastuzumab exhibit similar ADCC against HER2-positive cancer cell lines (Figure S4).